Gebelik ve Trombofili

Bremme KA. Haemostatic changes in pregnancy. Best Practice & Research Clinical Haematology 2003; 16: 153–168.

ACOG Practice Bulletin No. 197: Inherited Thrombophilias in Pregnancy. Obstetrics & Gynecology 2018; 132: e18–e34.

Middeldorp S, Nieuwlaat R, Baumann Kreuziger L, et al. American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing. Blood Advances 2023; 7: 7101–7138.

Royal College of Obstetricians and Gynaecologists. Reducing the Risk of Venous Thromboembolism During Pregnancy and the Puerperium, https://www.rcog.org.uk/globalassets/documents/guidelines/gtg-37a.pdf (2015).

Croles F, Borjas-Howard J, Nasserinejad K, et al. Risk of Venous Thrombosis in Antithrombin Deficiency: A Systematic Review and Bayesian Meta-analysis. Semin Thromb Hemost 2018; 44: 315–326.

Kobayashi T, Sugiura K, Ojima T, et al. Thrombosis-related characteristics of pregnant women with antithrombin deficiency, protein C deficiency and protein S deficiency in Japan. Thrombosis J 2024; 22: 18.

Croles FN, Nasserinejad K, Duvekot JJ, et al. Pregnancy, thrombophilia, and the risk of a first venous thrombosis: systematic review and bayesian meta-analysis. BMJ 2017; j4452.

Ryu J, Rämö JT, Jurgens SJ, et al. Thrombosis risk in single- and double-heterozygous carriers of factor V Leiden and prothrombin G20210A in FinnGen and the UK Biobank. Blood 2024; 143: 2425–2432.

Klein K, Wing S, Chen L, et al. The Net Benefit of Venous Thromboembolism Prophylaxis in Mild-Risk Thrombophilia and Pregnancy: A Systematic Review and Meta-Analysis. Blood 2023; 142: 1272–1272.

Beyler Ö, Baş H, Balık B, et al. Hereditary thrombophilia and recurrent pregnancy loss: is it time to reassess routine genetic testing? JCHOR 2025; 3: 22–26.

Kjellberg U, Van Rooijen M, Bremme K, et al. Factor V Leiden mutation and pregnancy-related complications. American Journal of Obstetrics and Gynecology 2010; 203: 469.e1-469.e8.

Silver RM, Zhao Y, Spong CY, et al. Prothrombin Gene G20210A Mutation and Obstetric Complications. Obstetrics & Gynecology 2010; 115: 14–20.

Liew S-C, Gupta ED. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: Epidemiology, metabolism and the associated diseases. European Journal of Medical Genetics 2015; 58: 1–10.

Liu X, Chen Y, Ye C, et al. Hereditary thrombophilia and recurrent pregnancy loss: a systematic review and meta-analysis. Human Reproduction 2021; 36: 1213–1229.

Kovalevsky G, Gracia CR, Berlin JA, et al. Evaluation of the Association Between Hereditary Thrombophilias and Recurrent Pregnancy Loss: A Meta-analysis. Arch Intern Med 2004; 164: 558.

Alijotas-Reig J, Esteve-Valverde E, Anunciación-Llunell A, et al. Pathogenesis, Diagnosis and Management of Obstetric Antiphospholipid Syndrome: A Comprehensive Review. JCM 2022; 11: 675.

Schreiber K, Sciascia S, De Groot PG, et al. Antiphospholipid syndrome. Nat Rev Dis Primers 2018; 4: 17103.

Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of Thrombosis and Haemostasis 2006; 4: 295–306.

Liu X, Zhu L, Liu H, et al. Non-criteria antiphospholipid antibodies in antiphospholipid syndrome: Diagnostic value added. Front Immunol 2022; 13: 972012.

Sebire NJ. Defective endovascular trophoblast invasion in primary antiphospholipid antibody syndrome-associated early pregnancy failure. Human Reproduction 2002; 17: 1067–1071.

Mulla MJ, Myrtolli K, Brosens JJ, et al. Antiphospholipid Antibodies Limit Trophoblast Migration by Reducing IL‐6 Production and STAT3 Activity. American J Rep Immunol 2010; 63: 339–348.

D’Ippolito S, Barbaro G, Paciullo C, et al. Antiphospholipid Syndrome in Pregnancy: New and Old Pathogenetic Mechanisms. IJMS 2023; 24: 3195.

Gharavi AE, Pierangeli SS, Levy RA, et al. Mechanisms of Pregnancy Loss in Antiphospholipid Syndrome: Clinical Obstetrics and Gynecology 2001; 44: 11–19.

Murvai VR, Galiș R, Panaitescu A, et al. Antiphospholipid syndrome in pregnancy: a comprehensive literature review. BMC Pregnancy Childbirth 2025; 25: 337.

Branch DW, Lim MY. How I diagnose and treat antiphospholipid syndrome in pregnancy. Blood 2024; 143: 757–768.

Beça S, Borrell M, Cervera R, et al. Non-Criteria Obstetric Antiphospholipid Syndrome: Myth or Reality? JCM 2025; 14: 1299.

Forastiero R, Martinuzzo M. The emerging role of multiple antiphospholipid antibodies positivity in patients with antiphospholipid syndrome. Expert Review of Clinical Immunology 2015; 11: 1255–1263.

Bradáčová P, Slavík L, Skoumalová A, et al. Determination of Thrombogenicity Levels of Various Antiphospholipid Antibodies by a Modified Thrombin Generation Assay in Patients with Suspected Antiphospholipid Syndrome. IJMS 2022; 23: 8973.

Patriarcheas V, Tsamos G, Vasdeki D, et al. Antiphospholipid Syndrome: A Comprehensive Clinical Review. JCM 2025; 14: 733.

Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Annals of the Rheumatic Diseases 2019; 78: 1296–1304.

Guerby P, Fillion A, O’Connor S, et al. Heparin for preventing adverse obstetrical outcomes in pregnant women with antiphospholipid syndrome, a systematic review and meta-analysis. Journal of Gynecology Obstetrics and Human Reproduction 2021; 50: 101974.

Ziakas PD, Pavlou M, Voulgarelis M. Heparin Treatment in Antiphospholipid Syndrome With Recurrent Pregnancy Loss: A Systematic Review and Meta-Analysis. Obstetrics & Gynecology 2010; 115: 1256–1262.

Barros VIPVLD, Igai AMK, Oliveira ALMLD, et al. Obstetric antiphospholipid syndrome: Number 6 - June 2021. Rev Bras Ginecol Obstet 2021; 43: 495–501.

Gerde M, Ibarra E, Mac Kenzie R, et al. The impact of hydroxychloroquine on obstetric outcomes in refractory obstetric antiphospholipid syndrome. Thrombosis Research 2021; 206: 104–110.

Mekinian A, Lazzaroni MG, Kuzenko A, et al. The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study. Autoimmunity Reviews 2015; 14: 498–502.

Bertolaccini ML, Contento G, Lennen R, et al. Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome. Journal of Autoimmunity 2016; 75: 30–38.

Ruffatti A, Tonello M, Hoxha A, et al. Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study. Thromb Haemost 2018; 47: 639–646.

Sophia Liontou, Maria Dagla, Victoria Vivilaki, et al. Antiphospholipid syndrome and pregnancy: A review article. World J Adv Res Rev 2025; 25: 143–151.

Lee EE, Jun JK, Lee EB. Management of Women with Antiphospholipid Antibodies or Antiphospholipid Syndrome during Pregnancy. J Korean Med Sci 2021; 36: e24.

Erton ZB, Sevim E, De Jesús GR, et al. Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (‘Registry’). Lupus Sci Med 2022; 9: e000633.

Leffert L, Butwick A, Carvalho B, et al. The Society for Obstetric Anesthesia and Perinatology Consensus Statement on the Anesthetic Management of Pregnant and Postpartum Women Receiving Thromboprophylaxis or Higher Dose Anticoagulants. Anesthesia & Analgesia 2018; 126: 928–944.

Zita A, Malinowski A, Carvalho J, et al. Risk of Recurrent Venous Thromboembolism and Hemorrhage Following Interruption of Anticoagulation at Delivery. Blood 2021; 138: 3233–3233.

Bates SM, Greer IA, Hirsh J, et al. Use of Antithrombotic Agents During Pregnancy. Chest 2004; 126: 627S-644S.

Marshall AL. Diagnosis, Treatment, and Prevention of Venous Thromboembolism in Pregnancy. Postgraduate Medicine 2014; 126: 25–34.

Bates SM, Greer IA, Pabinger I, et al. Venous Thromboembolism, Thrombophilia, Antithrombotic Therapy, and Pregnancy. Chest 2008; 133: 844S-886S.

Pabinger I, Vormittag R. Thrombophilia and pregnancy outcomes. Journal of Thrombosis and Haemostasis 2005; 3: 1603–1610.